Agios Pharmaceuticals (NASDAQ:AGIO) Upgraded at StockNews.com

StockNews.com upgraded shares of Agios Pharmaceuticals (NASDAQ:AGIO – Free Report) from a sell rating to a hold rating in a research note published on Wednesday morning. Other analysts also recently issued research reports about the stock. Royal Bank of Canada reduced their price objective on shares of Agios Pharmaceuticals from $43.00 to $42.00 and set […]

Leave a Reply

Your email address will not be published.

Previous post Equities Analysts Issue Forecasts for CAE Inc.’s Q1 2025 Earnings (NYSE:CAE)
Next post Rocket Lab USA’s (RKLB) “Overweight” Rating Reiterated at Cantor Fitzgerald